Protein_NN
kinase_NN
B_NN
-LRB-_-LRB-
c-Akt_NN
-RRB-_-RRB-
,_,
phosphatidylinositol_NN
3-kinase_NN
,_,
and_CC
STAT5_NN
are_VBP
activated_VBN
by_IN
erythropoietin_NN
-LRB-_-LRB-
EPO_NN
-RRB-_-RRB-
in_IN
HCD57_NN
erythroid_JJ
cells_NNS
but_CC
are_VBP
constitutively_RB
active_JJ
in_IN
an_DT
EPO-independent_JJ
,_,
apoptosis-resistant_JJ
subclone_NN
-LRB-_-LRB-
HCD57-SREI_NN
cells_NNS
-RRB-_-RRB-
._.

We_PRP
found_VBD
that_IN
erythropoietin_NN
-LRB-_-LRB-
EPO_NN
-RRB-_-RRB-
and_CC
stem_NN
cell_NN
factor_NN
-LRB-_-LRB-
SCF_NN
-RRB-_-RRB-
activated_VBD
protein_NN
kinase_NN
B_NN
-LRB-_-LRB-
PKB\/Akt_NN
-RRB-_-RRB-
in_IN
EPO-dependent_JJ
HCD57_NN
erythroid_JJ
cells_NNS
._.

To_TO
better_RBR
understand_VB
signals_NNS
controlling_VBG
proliferation_NN
and_CC
viability_NN
,_,
erythroid_JJ
cells_NNS
that_WDT
resist_VBP
apoptosis_NN
in_IN
the_DT
absence_NN
of_IN
EPO_NN
were_VBD
subcloned_VBN
and_CC
characterized_VBN
-LRB-_-LRB-
HCD57-SREI_NN
cells_NNS
-RRB-_-RRB-
._.

Constitutive_JJ
activations_NNS
of_IN
PKB\/Akt_NN
,_,
STAT5a_NN
,_,
and_CC
STAT5b_NN
were_VBD
noted_VBN
in_IN
these_DT
EPO-independent_JJ
cells_NNS
._.

PI3-kinase_NN
activity_NN
was_VBD
an_DT
upstream_JJ
activator_NN
of_IN
PKB\/Akt_NN
because_IN
the_DT
PI3-kinase_NN
inhibitor_NN
LY294002_NN
blocked_VBD
both_CC
constitutive_JJ
PKB\/Akt_NN
and_CC
factor-dependent_JJ
PKB\/Akt_NN
activity_NN
._.

The_DT
LY294002_NN
study_NN
showed_VBD
that_IN
proliferation_NN
and_CC
viability_NN
of_IN
both_CC
HCD57-SREI_NN
and_CC
HCD57_NN
cells_NNS
correlated_VBD
with_IN
the_DT
activity_NN
of_IN
PKB\/Akt_NN
;_:
however_RB
,_,
PKB\/Akt_NN
activity_NN
alone_RB
did_VBD
not_RB
protect_VB
these_DT
cells_NNS
from_IN
apoptosis_NN
._.

Treatment_NN
of_IN
HCD57_NN
cells_NNS
with_IN
SCF_NN
also_RB
activated_VBD
PKB\/Akt_NN
,_,
but_CC
did_VBD
not_RB
protect_VB
from_IN
apoptosis_NN
._.

This_DT
result_NN
suggested_VBD
that_IN
PKB\/PI3-kinase_NN
activity_NN
is_VBZ
necessary_JJ
but_CC
not_RB
sufficient_JJ
to_TO
promote_VB
viability_NN
and\/or_CC
proliferation_NN
._.

Constitutive_JJ
STAT5_NN
activity_NN
,_,
activated_VBN
through_IN
an_DT
unknown_JJ
pathway_NN
not_RB
including_VBG
JAK2_NN
or_CC
EPOR_NN
,_,
may_MD
act_VB
in_IN
concert_NN
with_IN
the_DT
constitutive_JJ
PI3-kinase\/PKB\/Akt_NN
pathway_NN
to_TO
protect_VB
the_DT
EPO-independent_JJ
HCD57-SREI_NN
cells_NNS
from_IN
apoptosis_NN
and_CC
promote_VB
limited_JJ
proliferation_NN
._.

